Alastair Hotblack
Overview
Explore the profile of Alastair Hotblack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jha R, Kinna A, Hotblack A, Bughda R, Bulek A, Gannon I, et al.
ACS Chem Biol
. 2024 Jan;
19(2):308-324.
PMID: 38243811
A versatile, safe, and effective small-molecule control system is highly desirable for clinical cell therapy applications. Therefore, we developed a two-component small-molecule control system based on the disruption of protein-protein...
2.
Mehra V, Agliardi G, Dias Alves Pinto J, Shafat M, Garai A, Green L, et al.
J Immunother Cancer
. 2023 Sep;
11(9).
PMID: 37709295
Background: AUTO1 is a fast off-rate CD19-targeting chimeric antigen receptor (CAR), which has been successfully tested in adult lymphoblastic leukemia. Tscm/Tcm-enriched CAR-T populations confer the best expansion and persistence, but...
3.
Hotblack A, Straathof K
Cancer Cell
. 2022 Jan;
40(1):11-13.
PMID: 35016025
Chimeric antigen receptors (CARs) allow redirection of T cells against any surface antigen. However, CARs require optimization to achieve activity against low-density antigens. Heitzeneder et al. perform an iterative adjustment...
4.
Hotblack A, Kokalaki E, Palton M, Weng-Kit Cheung G, Williams I, Manzoor S, et al.
Sci Rep
. 2021 Nov;
11(1):21902.
PMID: 34754016
Chimeric antigen receptor (CAR) T cells are a promising form of cancer immunotherapy, although they are often associated with severe toxicities. Here, we present a split-CAR design incorporating separate antigen...
5.
Agliardi G, Liuzzi A, Hotblack A, De Feo D, Nunez N, Stowe C, et al.
Nat Commun
. 2021 Jan;
12(1):444.
PMID: 33469002
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR)-based immunotherapy represents a promising therapeutic...
6.
Sledzinska A, Vila de Mucha M, Bergerhoff K, Hotblack A, Demane D, Ghorani E, et al.
Immunity
. 2020 Jan;
52(1):151-166.e6.
PMID: 31924474
In addition to helper and regulatory potential, CD4 T cells also acquire cytotoxic activity marked by granzyme B (GzmB) expression and the ability to promote rejection of established tumors. Here,...
7.
Stowe C, Burley T, Allan H, Vinci M, Kramer-Marek G, Ciobota D, et al.
Elife
. 2019 Oct;
8.
PMID: 31610848
Bioluminescence imaging (BLI) is ubiquitous in scientific research for the sensitive tracking of biological processes in small animal models. However, due to the attenuation of visible light by tissue, and...
8.
Hotblack A, Holler A, Piapi A, Ward S, Stauss H, Bennett C
Mol Ther
. 2018 Apr;
26(6):1471-1481.
PMID: 29628306
Ongoing clinical trials explore T cell receptor (TCR) gene therapy as a treatment option for cancer, but responses in solid tumors are hampered by the immunosuppressive microenvironment. The production of...
9.
Hotblack A, Seshadri S, Zhang L, Hamrang-Yousefi S, Chakraverty R, Escors D, et al.
Mol Ther
. 2017 Feb;
25(2):504-511.
PMID: 28153097
Recombinant lentiviral vectors (LVs) are highly effective vaccination vehicles that elicit protective T cell immunity in disease models. Dendritic cells (DCs) acquire antigen at sites of vaccination and migrate to...
10.
Holler A, Zech M, Ghorashian S, Pike R, Hotblack A, Velica P, et al.
Haematologica
. 2016 Jan;
101(4):482-90.
PMID: 26802053
Due to the lack of specificity for tumor antigens, allogeneic T-cell therapy is associated with graft-versus-host disease. Enhancing the anti-tumor specificity while reducing the graft-versus-host disease risk of allogeneic T...